Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Empagliflozin improves heart function in type 2 diabetes patients
Última actualización 6 de julio de 2026
Key finding
Empagliflozin resulted in a significant higher decrease in the primary endpoint E/e' ratio by -1.18 (95% CI -1.72/-0.65; P < 0.0001) compared with placebo.
This study evaluated the effects of empagliflozin on diastolic function in patients with type 2 diabetes and elevated end-diastolic pressure, finding significant improvements in various cardiovascular and metabolic parameters.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of empagliflozin on diastolic function in patients with type 2 diabetes and elevated end-diastolic pressure, finding significant improvements in various cardiovascular and metabolic parameters.
Clinical relevance
These findings are clinically significant as they suggest that empagliflozin not only aids in managing blood sugar levels but also improves heart function in patients with type 2 diabetes. This dual benefit could lead to better overall health outcomes and reduced cardiovascular risks in this population.
Keep in mind
The study's sample size may limit generalizability. The duration of the study may not capture long-term effects. Potential confounding factors were not fully controlled.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Jürgen HP, Claus J, Andreas S, et al. Empagliflozin Improves Diastolic Function in Patients with Type 2 Diabetes and Elevated End-Diastolic Pressure. Clinical Research in Cardiology. 2023;112(7):911-922. doi:10.1007/s00392-023-02164-w
Efectos Principales
Empagliflozin significantly decreased the left ventricular E/e' ratio by -1.18 (P < 0.0001).
Empagliflozin led to a significant decrease in body weight (P < 0.001).
Empagliflozin resulted in a significant decrease in HbA1c (P < 0.001).
Empagliflozin significantly increased hemoglobin levels (P < 0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Empagliflozin and Body weight, HbA1c, Hematocrit, and 4 more.
This study contributes evidence to
Primary intervention
Empagliflozin
Primary outcomes
- Body weight
- HbA1c
- Hematocrit
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
7
Evidence pairs
7
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
7
Evidence pairs
332
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 7 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
SGLT2 Inhibitors and HbA1c
Evidencia relacionada
Relación de evidencia
SGLT2 Inhibitors and Body Weight
Guardar evidencia
Tema de evidencia
HbA1c Reduction
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- 74
- Moderate
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Trackerleft ventricular E/e' ratio
Empagliflozin → left ventricular E/e' ratio
Empagliflozin → left ventricular E/e' ratio
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Empagliflozin improved the left ventricular E/e' ratio significantly.
- Participants experienced a significant reduction in body weight.
- HbA1c levels decreased significantly with empagliflozin treatment.
A quién se aplica
- Adults with type 2 diabetes.
- Patients experiencing elevated end-diastolic pressure.
Tener en Cuenta
- Results may not apply to populations outside the study demographics.
- Long-term effects of empagliflozin were not assessed in this trial.
- Further studies are needed to confirm these findings in diverse populations.
Entre Líneas
- The study's sample size may limit generalizability.
- The duration of the study may not capture long-term effects.
- Potential confounding factors were not fully controlled.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and Body Weight, SGLT2 Inhibitors and HbA1c.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
SGLT2 Inhibitors → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
View evidenceMedications
SGLT2 Inhibitors → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 74
- Moderate
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Body Weight Evidence Hub
All studies measuring Body Weight
3 studies
outcome_hubMeasures Body Weight as a key outcome.
HbA1c Evidence Hub
All studies measuring HbA1c
3 studies
outcome_hubMeasures HbA1c as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
3 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Empagliflozin and Body weight
Intervention: EmpagliflozinOutcome: Body weight
3 results
All studies on Empagliflozin and HbA1c
Intervention: EmpagliflozinOutcome: HbA1c
3 results
All studies on Empagliflozin
Intervention: Empagliflozin
3 results
All studies measuring Body weight
Outcome: Body weight
3 results
All studies measuring HbA1c
Outcome: HbA1c
3 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does SGLT2 Inhibitors improve HbA1c?
Strong Evidence
SGLT2 Inhibitors may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 74.4 | neutral | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors affect body weight?
Strong Evidence
SGLT2 Inhibitors may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Empagliflozin improve red blood cells?
Emerging Evidence
Empagliflozin appears to improve Red Blood Cells.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Red Blood Cells
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Empagliflozin improve left ventricular e/e' ratio?
Emerging Evidence
Empagliflozin appears to improve left ventricular E/e' ratio.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
left ventricular E/e' ratio
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesEmpagliflozin may improve nighttime blood sugar patterns in type 1 diabetesEmpagliflozin may reduce kidney disease biomarkers but shows mixed effects on albumin in early diabetesEmpagliflozin reduces body fluid volume in type 2 diabetes patientsEmpagliflozin improves glycemic control in HNF1A-MODY
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.